Other Information
+Added: Due to modifications in our management team’s reporting structure, effective May 3, 2023, the role of President―CNS Cancers held by Frank Leonard was determined by our Board of Directors to no longer meet the criteria of “executive officer” as defined in Rule 13b-7 or “officer” as defined in Rule 16a-1(f), in each case under the Securities Exchange Act of 1934, as amended.
+Added: Leonard’s role and responsibilities have not otherwise changed.
EXHIBIT INDEX
5 unchanged sentences
32.2* Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C.
+Added: 10.1 Employment Agreement, dated as of May 3, 2023, by and between NovoCure USA LLC and Francis Leonard #
101.INS Inline XBRL Instance Document X
7 unchanged sentences
* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
+Added: # Compensation plans and arrangements for executive officers and others.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NovoCure Limited
−Removed: October 27, 2022 /s/ Ashley Cordova
+Added: May 4, 2023 /s/ Ashley Cordova
Ashley Cordova
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.